70441-12-2

Usage

Classification

Psychoactive substance

Usage

Recreational drug

Effects

Stimulant and empathogenic

Form

Powder

Ingestion methods

Oral, inhalation, injection

Neurotransmitter interaction

Increases dopamine and norepinephrine levels

Resulting effects

Increased arousal and euphoria

Adverse effects

Insomnia, anxiety, addiction

Legal status

Controlled substance in many countries

Structural relation

Derivative of phenethylamine, related to cathinone

Upstream product

• 151-50-8 potassium cyanide 
• 108-94-1 cyclohexanone 
• 106-49-0 p-toluidine 
• 143-33-9 sodium cyanide 
• 7677-24-9 trimethylsilyl cyanide 

Downstream Products

• 1240789-11-0 1-p-tolyl-1,3-diazaspiro[4.5]decane-2,4-dione 
• 104931-50-2 1-(p-tolyl)-1,4-diazaspiro<5.5>undecane-3,5-dione 
• 19970-03-7 1--cyclohexancarbonsaeure-(1)-nitril 
• 99216-79-2 1-p-toluidino-cyclohexanecarboxylic acid 
• 636-82-8 cyclohexene-1-carboxylic acid 
• 175884-56-7 4-Imino-3-phenyl-1-p-tolyl-1,3-diaza-spiro[4.5]decan-2-one 
• 19969-98-3 1-<2-Chlor-p-toluidino>-cyclohexancarbonsaeure-(1)-nitril 
• 19970-02-6 1--cyclohexancarbonsaeure-(1)-nitril 
• 93865-32-8 1-(p-tolylamino)cyclohexanecarboxamide 

Relevant academic research and scientific papers

Gallic acid-functionalized magnetic nanoparticles: a convenient and green approach for synthesis of α-aminonitriles under solvent-free conditions

Abstract: Gallic acid-coated magnetic nanoparticles were efficiently prepared, characterized by Fourier transform infrared spectroscopy, X-ray diffraction, vibrating sample magnetometry, scanning electron microscopy, and transmission electron microscopy, and employed as an environmentally friendly and recyclable catalyst for one-pot synthesis of three-component reaction via Strecker reaction, incorporating aldehydes/ketones, amines, and trimethylsilyl cyanides under solvent-free conditions. Operational simplicity, product purity, natural resources and reusability of the catalyst are considered as evident features of this protocol which will hopefully develop into an inexpensive, efficient, and clean strategy for the synthesis of α-aminonitriles. Graphical abstract: [Figure not available: see fulltext.].

DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM

The present invention relates to novel compounds of general Formula (I), and also to cosmetic and pharmaceutical compositions containing such a compound.

DIARYLHYDANTOIN COMPOUNDS

The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for syntheszing them and using them in the treatment of hormone refractory prostate cancer.

Synthesis of new imidazolidinones, spiro-imidazolidinones and spiro-hydantoins

α-Alkyl/aryl-α-arylaminopropionitriles (1) and 1-arylamino-1-cyano-cyclohexanes/cyclopentanes (5) react with alkyl/arylisocyanates to afford new imidazolidinones (2, 3) and spiro-imidazolidinones (6, 7) respectively. Compounds 2 and 6 on hydrolysis give hydantoins (4) and spiro-hydantoins (8), respectively.